Indications:
For the treatment of adults with mild to moderate novel coronavirus pneumonia (COVID-19) with a high risk of progression to severe disease
Usage and dosage:
Take it orally. This product may or may not be taken with food. Tablets should be swallowed whole, not chewed, broken or crushed.
This product is a combination of Nematavir tablets and ritonavir tablets. Nematvir must be served with Ritonavir. If not taken with ritonavir, plasma levels of nematavir may not be sufficient to achieve the desired therapeutic effect.
The recommended dose is Nematavir 300mg(150mgx2 tablet) in combination with ritonavir 100mg(100mgx1 tablet) orally every 12 hours for 5 days. Take this product as soon as possible within 5 days of the diagnosis of COVD-19 and the onset of symptoms. It is also recommended to complete 5 days of treatment if a patient needs to be hospitalized for severe or critical COVID-19 after starting treatment with this product.
If the patient misses a dose of this product but does not exceed 8 hours of the usual dosing time, it should be replaced as soon as possible and continued according to the normal dosing schedule. If the patient misses a dose for more than 8 hours, the patient should not take the missed dose and should take the next dose at the prescribed time. Do not take a double dose to make up for a missed dose.
Therapeutic effect:
It reduces the risk of hospitalization or death by 89%, and reduces viral load by 10 times on the 5th day of medication, which is currently an effective small-molecule novel coronavirus oral specific drug.
